Antiverse

Antiverse, a BioTech firm specializing in AI-designed therapeutic antibodies for undruggable disease targets, has successfully secured £7 million in a Series A funding round.

Summary of transaction details:

• Value: £7 million
• Sector: BioTech / MedTech
• Advisor: Not disclosed
• Key Entities: Target: Antiverse, Lead Investor: Soulmates Ventures
• Location: Cardiff, UK

Note: This significant investment will enable Antiverse to scale its discovery platform, accelerate its internal drug pipeline, and advance lead antibody programmes towards in vivo efficacy studies, including a new research agreement with the Cystic Fibrosis Foundation to target historically difficult proteins.